Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangart has entered into a Cooperative Research And Development Agreement (CRADA) with the US Navy to evaluate its investigational biopharmaceutical product MP4 as a treatment for traumatic brain injury (TBI) in combat casualties.
Subscribe to our email newsletter
Sangart has entered into this CRADA with the US Naval Medical Research Center and the Uniformed Services University of Health Sciences.
The agreement will allow the US Navy to evaluate the oxygen carrying capacity and effectiveness of MP4 in traumatic brain injury.
Sangart president and CEO Brian O’Callaghan said that they look forward to working with the US Navy to evaluate MP4 in this important potential application.
"If these studies result in positive findings for MP4, it could potentially lead to better treatment options for the many service people and civilians that are victims of traumatic brain injury," O’Callaghan said.